Latest Innovation News

Dicker Data announces the departure of co-founder David Dicker from CEO and Chairman roles, transitioning leadership to a seasoned executive team under co-founder Fiona Brown’s Executive Chairmanship.

Cynata Therapeutics confirms that the recent FDA orphan-drug exclusivity granted to Ryoncil® will not block approval of its CYP-001 therapy, highlighting key differences in drug composition and patient indications.

Recce Pharmaceuticals has successfully raised A$8.4 million through an entitlement offer and placement to fund pivotal Phase 3 clinical trials, advancing its synthetic anti-infective pipeline towards commercialisation in 2026.

ECS Botanics is on track for a record-breaking FY25 harvest with a 50% production increase and new premium product launches, signaling strong growth and a positive cash flow outlook.

Etherstack plc has reported its highest ever half-year cash receipts, surpassing US$7 million in the first half of FY2025, signaling strong momentum and a promising revenue outlook for the year.

Norwood Systems has successfully completed a $500,000 oversubscribed placement, positioning itself for accelerated growth and strategic debt reduction. The funds will support market expansion, product innovation, and operational improvements.

Appen Limited reported robust 2024 results with a 16% revenue increase excluding Google and a return to profitability, driven by generative AI projects and China market expansion. The company outlines a confident 2025 strategy focused on AI data quality, operational efficiency, and sustained growth.

Tasman Resources Ltd has announced a renounceable pro-rata rights issue aiming to raise up to $3.68 million to finance exploration drilling at its Parkinson Dam project and reduce shareholder debt. Major shareholders plan to fully subscribe, using loan repayments to offset their entitlements.

Chimeric Therapeutics reports encouraging interim results from its ADVENT-AML Phase 1B trial, with two of three newly diagnosed AML patients achieving remission using their novel CORE-NK cell therapy combined with standard treatment.

oOh!media Limited reports robust revenue growth momentum continuing into 2025, driven by strong contract wins and disciplined cost management. The company expects sustained market share gains in the expanding Out of Home advertising sector.

Proteomics International Laboratories has secured a key Chinese patent for its OxiDx oxidative stress test, broadening its intellectual property coverage across major global markets until 2039. This milestone reinforces the company’s position in precision diagnostics for sports and veterinary health.

Rhythm Biosciences’ subsidiary Genetype has landed a pivotal 12-month contract with the University of Melbourne to provide advanced breast cancer risk assessments, marking a significant step in personalised cancer screening.